Radiotherapy (RT) is a highly effective anti-cancer treatment that is delivered to over half of all cancer patients. In addition to the well documented direct cytotoxic effects, RT can induce immunomodulatory effects to the tumour and surrounding tissues. These effects are thought to underlie the so-called 'abscopal responses', where RT generates systemic antitumour immunity outside of the irradiated tumour. In addition, RT may also result in an inflammatory immune response in the normal tissues surrounding the tumour. The full scope of these immune changes remains unclear but is likely to involve multiple tissue components and immune mediators. These include immune cells, the extracellular matrix, endothelial and epithelial cells and a myriad of chemokines and cytokines, including TGFβ, which is known to play a key role. In normal tissues exposed to RT during cancer therapy, acute immune changes may ultimately lead to chronic inflammation and RT-induced toxicity and organ dysfunction, which limits the quality of life of cancer survivors. Here, we discuss the emerging understanding of RT-induced immune effects with a particular focus on the lung and gut and the potential immune cross-talk that occurs between these tissues.